Fig. 4

A Mass spectrometry images of PTX distribution in tumour tissues of parental SKOV3 or SKOV3/HAS3 after repeated treatment, q7dx2. Three tumours were analysed for each group. One representative section of three analysed for each tumour is shown. B GLSZM features (mean, CV%, LZE-Large-Zone Emphasis, HGZE-High Grey-level Zone Emphasis, IV-Intensity Variability, GLNn-normalised Grey-Level Non-uniformity and DHI-Drug Homogeneity Index) describing PTX distribution in SKOV3 or C SKOV3/HAS3 tumours 4 h after PTX, with or without PEGPH20 pre-treatment (repeated treatment, q7dx2) * Student's t test: p-value< 0.05. D Tumour concentrations of PTX in the second half of the same tumours analysed for MSI after PEGPH20 or vehicle pre-treatment (repeated treatment, q7dx2) **Student's t test: p-value< 0.01